menu
    • menu
    [{"orgOrder":0,"company":"Center for Breakthrough Medicines","sponsor":"Virion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Center for Breakthrough Medicines","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Center for Breakthrough Medicines \/ Virion Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Center for Breakthrough Medicines \/ Virion Therapeutics"},{"orgOrder":0,"company":"Center for Breakthrough Medicines","sponsor":"Achilles Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"ATL001","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Center for Breakthrough Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Center for Breakthrough Medicines \/ Center for Breakthrough Medicines","highestDevelopmentStatusID":"7","companyTruncated":"Center for Breakthrough Medicines \/ Center for Breakthrough Medicines"},{"orgOrder":0,"company":"Center for Breakthrough Medicines","sponsor":"jCyte","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Allogeneic Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Center for Breakthrough Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Center for Breakthrough Medicines \/ Center for Breakthrough Medicines","highestDevelopmentStatusID":"8","companyTruncated":"Center for Breakthrough Medicines \/ Center for Breakthrough Medicines"}]

    Find Clinical Drug Pipeline Developments & Deals by Center for Breakthrough Medicines

    Menu

    Center for Breakthrough Medicines

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Center for Breakthrough Medicines

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Center for Breakthrough Medicines

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VRON-0200,Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Virion Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Center for Breakthrough Medicines and Virion Therapeutics Announce Strategic Partnership to Manufacture Virion...

                            Details : Under the terms of the collaboration, CBM will manufacture and partner with Virion on their checkpoint modifier clinical development programs, including the First-in-Human VRON-0200 immunotherapy for patients with chronic Hepatitis B Virus (HBV) infectio...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            February 22, 2023

                            Lead Product(s) : VRON-0200,Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Virion Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Center for Breakthrough Medicines

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Center for Breakthrough Medicines

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATL001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Achilles Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US

                            Details : The second GMP manufacturing site will initially support Achilles’ proprietary VELOS™ manufacturing process with an annual capacity of 200 cNeT (Clonal NeoantigenT-cells) doses at peak production. The Company’s first US GMP manufacturing facility t...

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 04, 2022

                            Lead Product(s) : ATL001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Achilles Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Center for Breakthrough Medicines

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Center for Breakthrough Medicines

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Human Retinal Progenitor Cell

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Recipient : jCyte

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Center for Breakthrough Medicines and jCyte Announce Strategic Partnership to Manufacture jCyte’s Innovative...

                            Details : Under the terms of the agreement, CBM will provide Phase 3 clinical trial supplies and commercial drug product following Biologics License Application (BLA) approval of jCyte’s proprietary jCell platform technology working on human retinal progenitor c...

                            Product Name : jCell

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 20, 2022

                            Lead Product(s) : Allogeneic Human Retinal Progenitor Cell

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Recipient : jCyte

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth